AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15983779 — intervention group
Group type: EXPERIMENTAL
Intervention: ClariFlex silicone IOL
Number of subjects: 47
Study 15983779 — intervention group
Group type: COMPARATOR
Intervention: AR40e hydrophobic acrylic IOL
Number of subjects: 47
Study 19768884 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 0
Study 19768884 — intervention group
Group type: EXPERIMENTAL
Intervention: Population service screening (organized, community-based screening)
Number of subjects: 0
Study 19768884 — intervention group
Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 0
Study 10990391 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemonucleolysis (CN)
Number of subjects: 22
Study 10990391 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated percutaneous discectomy (APD)
Number of subjects: 22
Study 8706305 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 12 months
Number of subjects: 25
Study 8706305 — intervention group
Group type: COMPARATOR
Intervention: Dual-energy X-ray absorptiometry (DEXA)
Number of subjects: 25
Study 8706305 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body water (TBW)
Number of subjects: 25
Study 8706305 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body potassium (TBK)
Number of subjects: 25
Study 8706305 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectric impedance (BIA)
Number of subjects: 25
Study 1414179 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate and 2-chloroprocaine followed by continuous bupivacaine epidural infusion
Number of subjects: 31
Study 1414179 — intervention group
Group type: COMPARATOR
Intervention: Normal saline and 2-chloroprocaine followed by continuous bupivacaine epidural infusion
Number of subjects: 31
Study 2991708 — intervention group
Group type: EXPERIMENTAL
Intervention: Invited group (screening)
Number of subjects: 21000
Study 2991708 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21000
Study 30064725 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoelace technique
Number of subjects: 21
Study 30064725 — intervention group
Group type: COMPARATOR
Intervention: VAC wounds
Number of subjects: 21
Study 30064725 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall primary closure
Number of subjects: 21
Study 27125818 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI prescribing prior to psychological treatment
Number of subjects: 465
Study 27125818 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI prescribing based on clinical characteristics
Number of subjects: 465
Study 27125818 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI prescribing variation
Number of subjects: 465
Study 27125818 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical practitioners' considerations
Number of subjects: 465
Study 25037644 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive decision-aid smartphone smoking cessation application (app)
Number of subjects: 0
Study 25037644 — intervention group
Group type: COMPARATOR
Intervention: Control app containing only smoking cessation information
Number of subjects: 0
Study 23103663 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1800
Study 23103663 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1800
Study 19949319 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta‐THC
Number of subjects: 8
Study 19949319 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 8
Study 19949319 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 8
Study 19949319 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 8
Study 19949319 — intervention group
Group type: EXPERIMENTAL
Intervention: All drugs tested
Number of subjects: 8
Study 17873306 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg three times a day orally) and alpha-tocopherol (300 mg twice a day orally) during radiotherapy, followed by 400 mg once a day and 300 mg once a day for 3 months after radiotherapy.
Number of subjects: 91
Study 17873306 — intervention group
Group type: COMPARATOR
Intervention: Control group (47 patients)
Number of subjects: 91
Study 16164120 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine surfactant (Survanta)
Number of subjects: 44
Study 16164120 — intervention group
Group type: COMPARATOR
Intervention: Porcine surfactant (Surfacen)
Number of subjects: 44
Study 11966934 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% amine fluoride, 0.028% sodium fluoride, 0.03% triclosan mouthrinse
Number of subjects: 12
Study 11966934 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine solution (positive control)
Number of subjects: 12
Study 11966934 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 12
Study 10093981 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment (intravenous methylprednisolone 1 g per day for 3 consecutive days at the beginning of months 1, 3, and 5, plus oral prednisone 0.5 mg/kg on alternate days for 6 months)
Number of subjects: 86
Study 10093981 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy alone
Number of subjects: 86
Study 8527618 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole plus clarithromycin
Number of subjects: 154
Study 8527618 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole plus placebo
Number of subjects: 154
Study 2257861 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug A once daily in the evening
Number of subjects: 24
Study 2257861 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug A b.d.
Number of subjects: 24
Study 2257861 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug B b.d.
Number of subjects: 24
Study 2257861 — intervention group
Group type: COMPARATOR
Intervention: Drug A b.d. and Drug B b.d.
Number of subjects: 24
Study 7411244 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, high-beef diet (cooked rare)
Number of subjects: 0
Study 7411244 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, high-beef diet (cooked medium)
Number of subjects: 0
Study 7411244 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, high-beef diet (cooked well-done)
Number of subjects: 0
Study 7411244 — intervention group
Group type: COMPARATOR
Intervention: Customary mixed-western diet (pre- and post-experimental periods)
Number of subjects: 0
Study 31288854 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing appointments
Number of subjects: 120
Study 31288854 — intervention group
Group type: COMPARATOR
Intervention: Traditional appointments
Number of subjects: 120
Study 28378573 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided sedation
Number of subjects: 113
Study 28378573 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 113
Study 25560201 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (selective serotonin reuptake inhibitor) for 3 weeks
Number of subjects: 32
Study 25560201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23440348 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kV/280 HU
Number of subjects: 181
Study 23440348 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 kV/350 HU
Number of subjects: 181
Study 23440348 — intervention group
Group type: COMPARATOR
Intervention: 120 kV/350 HU
Number of subjects: 181
Study 21679328 — intervention group
Group type: EXPERIMENTAL
Intervention: Skiing intervention lasting 12 weeks
Number of subjects: 0
Study 21679328 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 18373121 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cc of fibrin glue intraoperatively
Number of subjects: 58
Study 18373121 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline irrigation
Number of subjects: 58
Study 16491234 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (1-year specialists)
Number of subjects: 21
Study 16491234 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (5-year specialists)
Number of subjects: 21
Study 16491234 — intervention group
Group type: COMPARATOR
Intervention: Group 3 (10-year specialists)
Number of subjects: 21
Study 14750421 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydacorn (1 mg dihydroergotamine, 40 mg caffeine, 100 mg diphenylhydantoine)
Number of subjects: 36
Study 14750421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 11094565 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 1518
Study 11094565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1518
Study 9327312 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal vortex pump (Biopump, Medtronic Biomedicus Inc, MN)
Number of subjects: 34
Study 9327312 — intervention group
Group type: COMPARATOR
Intervention: Standard twin roller pump
Number of subjects: 34
Study 8238826 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl/bupivacaine (2.5 micrograms.ml‐1 of fentanyl)
Number of subjects: 60
Study 8238826 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil/bupivacaine (0.25 micrograms.ml‐1 of sufentanil)
Number of subjects: 60
Study 8238826 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl/bupivacaine
Number of subjects: 60
Study 8238826 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil/bupivacaine
Number of subjects: 60
Study 3519107 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 43
Study 3519107 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP)
Number of subjects: 43
Study 3519107 — intervention group
Group type: COMPARATOR
Intervention: Control group (Triflo deep-breathing device)
Number of subjects: 43
Study 29140155 — intervention group
Group type: EXPERIMENTAL
Intervention: Calmangafodipir 2 µmol/kg
Number of subjects: 173
Study 29140155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 29140155 — intervention group
Group type: EXPERIMENTAL
Intervention: Calmangafodipir 5 µmol/kg
Number of subjects: 173
Study 27491663 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronically delivered, multicomponent interventions including feedback of antibiotic prescribing reports, educational tools, and a webinar for 12 months.
Number of subjects: 0
Study 27491663 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group).
Number of subjects: 0
Study 24969367 — intervention group
Group type: EXPERIMENTAL
Intervention: TACT intervention package (including interactive small group workshops, feedback text messages, motivational text messages, patient information leaflets and posters)
Number of subjects: 231
Study 20937615 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g/kg alcohol
Number of subjects: 30
Study 20937615 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/kg alcohol
Number of subjects: 30
Study 20937615 — intervention group
Group type: COMPARATOR
Intervention: 0.0 g/kg alcohol
Number of subjects: 30
Study 20838118 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (200 μg/kg initially; 100 μg/kg at 1 hour and 3 hours)
Number of subjects: 573
Study 20838118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 573
Study 20838118 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa
Number of subjects: 573
Study 18391486 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day
Number of subjects: 325
Study 18391486 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/day
Number of subjects: 325
Study 18391486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 15715599 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (systemically or intravaginally)
Number of subjects: 0
Study 15715599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12903609 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) as uterine distension medium
Number of subjects: 38
Study 12903609 — intervention group
Group type: COMPARATOR
Intervention: Normal saline as uterine distension medium
Number of subjects: 38
Study 10770366 — intervention group
Group type: EXPERIMENTAL
Intervention: Achalasia
Number of subjects: 1144
Study 10770366 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflux disease
Number of subjects: 1144
Study 10770366 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 1144
Study 10770366 — intervention group
Group type: EXPERIMENTAL
Intervention: Achalasia, no reflux, normal motility group, and controls
Number of subjects: 1144
Study 8728351 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg for days 1-3, 20 mg for days 4-14)
Number of subjects: 0
Study 8728351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1906716 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate inhalation aerosol preparation 1
Number of subjects: 15
Study 1906716 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate inhalation aerosol preparation 2
Number of subjects: 15
Study 6343729 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with 10 cm H2O of PEEP
Number of subjects: 139
Study 6343729 — intervention group
Group type: COMPARATOR
Intervention: No PEEP
Number of subjects: 139
Study 30947418 — intervention group
Group type: EXPERIMENTAL
Intervention: Angle‐Aided Circle Detection (AACD) algorithm based on the randomized Hough transform
Number of subjects: 0
Study 30947418 — intervention group
Group type: COMPARATOR
Intervention: Traditional Hough transform
Number of subjects: 0
Study 28614197 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Evaluation of Sedation Titration for Respiratory Failure protocol
Number of subjects: 1255
Study 28614197 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1255
Study 28614197 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation patients
Number of subjects: 1255
Study 28614197 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal membrane oxygenation patients managed per Randomized Evaluation of Sedation Titration for Respiratory Failure protocol
Number of subjects: 1255
Study 27464071 — intervention group
Group type: EXPERIMENTAL
Intervention: Watch Me Move program plus standard of care physiotherapy (n = 24)
Number of subjects: 40
Study 27464071 — intervention group
Group type: COMPARATOR
Intervention: Standard of care physiotherapy (n = 16)
Number of subjects: 40
Study 24733007 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pharmacotherapy
Number of subjects: 1295
Study 24733007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum alone
Number of subjects: 1295
Study 24733007 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 1295
Study 24733007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 1295
Study 24733007 — intervention group
Group type: EXPERIMENTAL
Intervention: CHRNA5‐A3‐B4 variants
Number of subjects: 1295
Study 22685670 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (400 mg) until delivery
Number of subjects: 72
Study 22685670 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate (control group)
Number of subjects: 72
Study 19101111 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon valvuloplasty (BV)
Number of subjects: 7
Study 17258626 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide [Ca(OH)2]
Number of subjects: 33
Study 17258626 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gel (CHX)
Number of subjects: 33
Study 17258626 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of calcium hydroxide and chlorhexidine [Ca(OH)2/CHX]
Number of subjects: 33
Study 17258626 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 33
Study 16322398 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 (BIAsp30) administered via multiple daily injections for 12 weeks
Number of subjects: 23
Study 11910301 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 84
Study 11910301 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 84
Study 9637640 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral approach to popliteal block (PB) with 40 ml 1.5% alkalinized mepivacaine with 1:200,000 epinephrine.
Number of subjects: 50
Study 9637640 — intervention group
Group type: COMPARATOR
Intervention: Posterior approach to popliteal block (PB) with 40 ml 1.5% alkalinized mepivacaine with 1:200,000 epinephrine.
Number of subjects: 50
Study 8202904 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory questionnaire and spirometric tests
Number of subjects: 409
Study 8202904 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometric tests
Number of subjects: 409
Study 8202904 — intervention group
Group type: COMPARATOR
Intervention: Smoking status
Number of subjects: 409
Study 2973269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide inhaled as a dry powder (40 micrograms)
Number of subjects: 15
Study 2973269 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide by pressurized aerosol (two puffs of 20 micrograms; total 40 micrograms)
Number of subjects: 15
Study 31771424 — intervention group
Group type: EXPERIMENTAL
Intervention: Senhance robotic system
Number of subjects: 40
Study 31771424 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic technique
Number of subjects: 40
Study 29871809 — intervention group
Group type: EXPERIMENTAL
Intervention: MOM hip prostheses
Number of subjects: 95
Study 28244205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan eligibility criteria applied to patients on target doses of ACE inhibitors or ARBs
Number of subjects: 6131
Study 28244205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan eligibility criteria applied to all patients regardless of background medication
Number of subjects: 6131
Study 28244205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan eligibility criteria applied to patients with HFrEF
Number of subjects: 6131
Study 28244205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan eligibility criteria applied ignoring background medication
Number of subjects: 6131
Study 25819691 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral eliglustat
Number of subjects: 160
Study 25819691 — intervention group
Group type: COMPARATOR
Intervention: Imiglucerase
Number of subjects: 160
Study 23894336 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (risperidone and aripiprazole)
Number of subjects: 69
Study 23894336 — intervention group
Group type: COMPARATOR
Intervention: Control group (race-matched subjects without schizophrenia)
Number of subjects: 69
Study 21199699 — intervention group
Group type: EXPERIMENTAL
Intervention: 2009 A/H1N1 MF59‐adjuvanted influenza vaccine administered simultaneously with seasonal virosomal‐adjuvanted influenza vaccine
Number of subjects: 72
Study 21199699 — intervention group
Group type: COMPARATOR
Intervention: 2009 A/H1N1 MF59‐adjuvanted influenza vaccine administered sequentially with seasonal virosomal‐adjuvanted influenza vaccine
Number of subjects: 72
Study 21199699 — intervention group
Group type: COMPARATOR
Intervention: Seasonal vaccine administered alone
Number of subjects: 72
Study 21199699 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of pandemic and seasonal vaccines
Number of subjects: 72
Study 18653228 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg once daily
Number of subjects: 410
Study 18653228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 18653228 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 410
Study 17175653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to change health behaviour
Number of subjects: 0
Study 14680667 — intervention group
Group type: EXPERIMENTAL
Intervention: St. George's Respiratory Questionnaire (SGRQ)
Number of subjects: 84
Study 14680667 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling Thermometer (FT)
Number of subjects: 84
Study 11600556 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (60 mg) premeal (‐10,‐1 min)
Number of subjects: 12
Study 11600556 — intervention group
Group type: COMPARATOR
Intervention: Nateglinide (60 mg) postmeal (+10 min)
Number of subjects: 12
Study 11600556 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (60 mg) before meals (10 min before)
Number of subjects: 12
Study 11600556 — intervention group
Group type: COMPARATOR
Intervention: Nateglinide (60 mg) after meals (10 min after)
Number of subjects: 12
Study 9732163 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% PFPE-containing o/w emulsion
Number of subjects: 10
Study 9732163 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% PFPE-containing o/w emulsion
Number of subjects: 10
Study 9732163 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0% PFPE-containing o/w emulsion
Number of subjects: 10
Study 9732163 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0% PFPE-containing o/w emulsion
Number of subjects: 10
Study 9732163 — intervention group
Group type: COMPARATOR
Intervention: Emulsion base alone
Number of subjects: 10
Study 7981071 — intervention group
Group type: EXPERIMENTAL
Intervention: OND/MPD (8 mg OND i.v. injection and 120 mg MPD i.v. injection before chemotherapy, followed by 8 mg OND tablet and 16 mg MPD tablet orally for 3-5 days)
Number of subjects: 102
Study 7981071 — intervention group
Group type: COMPARATOR
Intervention: OND (8 mg OND plus placebo i.v. injection before chemotherapy, followed by 8 mg OND tablet and placebo orally for 3-5 days)
Number of subjects: 102
Study 7981071 — intervention group
Group type: EXPERIMENTAL
Intervention: OND/MPD
Number of subjects: 102
Study 2663321 — intervention group
Group type: EXPERIMENTAL
Intervention: miglitol (BAY‐m‐1099)
Number of subjects: 13
Study 2663321 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 13
Study 30610502 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chitosan and Dan-shen injection
Number of subjects: 400
Study 30610502 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan
Number of subjects: 400
Study 30610502 — intervention group
Group type: EXPERIMENTAL
Intervention: Dan-shen
Number of subjects: 400